drugset
drugset / Trial / NCT02684279

Dasotraline Binge Eating Disorder Extension Study

NCT02684279 ↗

Phase 3 Completed 533 enrolled Sumitomo Pharma America, Inc.
NaSingle-groupOpen-labelTreatment

Summary

Binge Eating Disorder Extension Study.

Timeline

Start
2016-02-29
Primary completion
2019-06-24
Completion
2019-06-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Dasotraline Small molecule 4 mg —
Subject Dasotraline Small molecule 6 mg —
Subject Dasotraline Small molecule 8 mg —

Indications

binge eating disorder